Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have earned an average rating of “Moderate Buy” from the eight analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $20.57.

A number of brokerages have weighed in on STOK. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Thursday, April 4th. TD Cowen raised shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 26th. JPMorgan Chase & Co. raised their price objective on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research note on Tuesday, March 26th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Monday.

Stoke Therapeutics Trading Up 0.6 %

Shares of STOK opened at $11.94 on Wednesday. The firm has a market capitalization of $622.31 million, a price-to-earnings ratio of -5.04 and a beta of 0.82. The firm’s fifty day simple moving average is $10.23 and its 200-day simple moving average is $6.68. Stoke Therapeutics has a twelve month low of $3.35 and a twelve month high of $16.40.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, March 25th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.02. The company had revenue of $2.80 million for the quarter, compared to analysts’ expectations of $3.70 million. On average, analysts predict that Stoke Therapeutics will post -2.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Edward M. Md Kaye sold 11,150 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the sale, the chief executive officer now directly owns 69,350 shares in the company, valued at $423,035. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Edward M. Md Kaye sold 11,150 shares of the business’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the transaction, the chief executive officer now directly owns 69,350 shares of the company’s stock, valued at $423,035. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Skorpios Trust sold 3,600,000 shares of the stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total value of $41,760,000.00. Following the sale, the insider now directly owns 10,843,681 shares in the company, valued at approximately $125,786,699.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,622,741 shares of company stock worth $41,935,115. Insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors have recently modified their holdings of the company. Lynx1 Capital Management LP acquired a new stake in Stoke Therapeutics during the third quarter worth approximately $6,738,000. GSA Capital Partners LLP increased its position in Stoke Therapeutics by 514.7% during the third quarter. GSA Capital Partners LLP now owns 348,069 shares of the company’s stock worth $1,371,000 after purchasing an additional 291,443 shares during the last quarter. Birchview Capital LP raised its stake in Stoke Therapeutics by 147.1% during the fourth quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock worth $1,105,000 after purchasing an additional 125,000 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Stoke Therapeutics by 9.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 146,076 shares of the company’s stock valued at $576,000 after purchasing an additional 12,478 shares during the last quarter. Finally, Trexquant Investment LP grew its stake in shares of Stoke Therapeutics by 166.9% during the 3rd quarter. Trexquant Investment LP now owns 127,581 shares of the company’s stock valued at $503,000 after buying an additional 79,785 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.